A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
Overview
- Phase
- Phase 1
- Intervention
- AJM347
- Conditions
- Healthy Participants
- Sponsor
- EA Pharma Co., Ltd.
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Number of participants with any adverse event (AE)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This study will be conducted to determine the safety and tolerability of single and multiple oral ascending doses of AJM347 in healthy male participants, and to assess the pharmacodynamic response following single and multiple oral ascending doses of AJM347 in the same population. This study will also aim to determine the single and multiple oral ascending dose pharmacokinetics of AJM347 and its metabolite in healthy male participants, and to determine the effect of food on the single and multiple oral dose pharmacokinetics of AJM347 and its metabolite in the same population.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Main Inclusion Criteria for all participants:
- •Participants will be male
- •Participants will be in good health
- •Main Inclusion Criteria for Japanese participants:
- •Be ≥20 to ≤45 years of age
- •Have body mass index (BMI) ≥18.5 to ≤25.0 kilograms per meters squared (kg/m\^2)
- •Be Japanese
- •Main Inclusion Criteria for Caucasian participants:
- •Be ≥18 to ≤45 years of age
- •Have a BMI ≥18.5 to ≤30.0 kg/m\^2
Exclusion Criteria
- •Main Exclusion Criteria for all participants:
- •Participants will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated.
- •Participants who have donated or lost ≥200 milliliters (mL) blood within 1 month or ≥400 mL within 3 months prior to Check-in
- •Participants who have an abnormality in heart rate, blood pressure, temperature, or respiration rate at Screening
- •Participants who have:
- •a positive urine drugs of abuse screen;
- •a positive alcohol breath test
- •Participants who have an abnormality in the 12-lead electrocardiogram (ECG) at Screening
- •Participants who are still participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first dose administration
- •Participants who have a significant history of drug allergy, as determined by the Investigator
Arms & Interventions
Part 1: AJM347
Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
Intervention: AJM347
Part 1: Placebo
Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
Intervention: Placebo
Part 2: Low-dose AJM347
Caucasian and Japanese participants will receive a "low" dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods.
Intervention: AJM347
Part 2: High-dose AJM347
Caucasian and Japanese participants will receive a "high" dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups).
Intervention: AJM347
Part 3: AJM347
Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
Intervention: AJM347
Part 3: Placebo
Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
Intervention: Placebo
Outcomes
Primary Outcomes
Number of participants with any adverse event (AE)
Time Frame: Part 1, up to Days 7 to 9; Part 2, up to Days 7 to 9; Part 3, up to Day 15 (Parts 1, 2, and 3 are not continuous)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product.
Secondary Outcomes
- Number of participants with abnormal, clinically significant physical examination findings(Part 1, up to Days 7 to 9; Part 2, up to Days 7 to 9; Part 3, up to Day 15 (Parts 1, 2, and 3 are not continuous))
- Number of participants with abnormal, clinically significant vital sign values(Part 1, up to Days 7 to 9; Part 2, up to Days 7 to 9; Part 3, up to Day 15 (Parts 1, 2, and 3 are not continuous))
- Number of participants with abnormal, clinically significant 12-lead electrocardiogram (ECG) values(Part 1, up to Days 7 to 9; Part 2, up to Days 7 to 9; Part 3, up to Day 15 (Parts 1, 2, and 3 are not continuous))
- Number of participants with abnormal, clinically significant clinical laboratory values(Part 1, up to Days 7 to 9; Part 2, up to Days 7 to 9; Part 3, up to Day 15 (Parts 1, 2, and 3 are not continuous))
- Mean plasma concentrations of AJM347 and its metabolite(Part 1, Days 1 to 3; Part 2, Days 1 to 3; Part 3, Days 1 to 3, Day 7, Days 9 to 11 (Parts 1, 2, and 3 are not continuous))
- Mean urinary concentrations of AJM347 and its metabolite(Part 1, Days 1 to 3; Part 3, Days 1 to 10)
- Inhibition rate of ligand-binding activity(Part 1, Days 1 and 2; Part 3, Days 1 and 2, Days 7, 9, and 10)